TW202128648A - 人類免疫不全病毒複製之抑制劑 - Google Patents

人類免疫不全病毒複製之抑制劑 Download PDF

Info

Publication number
TW202128648A
TW202128648A TW109134208A TW109134208A TW202128648A TW 202128648 A TW202128648 A TW 202128648A TW 109134208 A TW109134208 A TW 109134208A TW 109134208 A TW109134208 A TW 109134208A TW 202128648 A TW202128648 A TW 202128648A
Authority
TW
Taiwan
Prior art keywords
methyl
chloro
pharmaceutically acceptable
pyrazol
indazol
Prior art date
Application number
TW109134208A
Other languages
English (en)
Chinese (zh)
Inventor
麥可 S 保席爾
凱爾 E 帕賽拉
瑪諾 帕特
艾瑞克 P 吉利斯
B 那拉辛胡路 奈度
Original Assignee
英商Viiv醫療保健英國(No 5)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商Viiv醫療保健英國(No 5)有限公司 filed Critical 英商Viiv醫療保健英國(No 5)有限公司
Publication of TW202128648A publication Critical patent/TW202128648A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
TW109134208A 2019-10-04 2020-09-30 人類免疫不全病毒複製之抑制劑 TW202128648A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962910684P 2019-10-04 2019-10-04
US62/910,684 2019-10-04

Publications (1)

Publication Number Publication Date
TW202128648A true TW202128648A (zh) 2021-08-01

Family

ID=73014547

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109134208A TW202128648A (zh) 2019-10-04 2020-09-30 人類免疫不全病毒複製之抑制劑

Country Status (6)

Country Link
US (1) US20230013823A1 (https=)
EP (1) EP4038061A1 (https=)
JP (1) JP2022552156A (https=)
AR (1) AR120150A1 (https=)
TW (1) TW202128648A (https=)
WO (1) WO2021064677A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20220370451A1 (en) * 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) 2024-02-05 2025-12-16 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ, インコーポレイテッド ピリジン誘導体およびhiv感染を処置するためのその使用
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
EP3774775B8 (en) * 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
EP3849982A1 (en) * 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) * 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US11541055B2 (en) * 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2971987T3 (es) * 2018-10-24 2024-06-10 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de inmunodeficiencia humana
JP7500555B2 (ja) * 2018-10-25 2024-06-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP4038068A1 (en) * 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
EP4038064B1 (en) * 2019-10-01 2024-02-21 VIIV Healthcare UK (No.5) Limited N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
US20220370451A1 (en) * 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
EP4114527A1 (en) * 2020-03-06 2023-01-11 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112022020933A2 (pt) * 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
MX2024004551A (es) * 2021-10-13 2024-06-26 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.

Also Published As

Publication number Publication date
US20230013823A1 (en) 2023-01-19
AR120150A1 (es) 2022-02-02
WO2021064677A1 (en) 2021-04-08
EP4038061A1 (en) 2022-08-10
JP2022552156A (ja) 2022-12-15

Similar Documents

Publication Publication Date Title
JP6861307B2 (ja) タンパク質調節因子として有用な複素環式アミド
TW202128648A (zh) 人類免疫不全病毒複製之抑制劑
US20240374598A1 (en) Inhibitors of human immunodeficiency virus replication
WO2023044046A1 (en) Bcl-xl degraders and uses thereof
CN115776891A (zh) Stat降解剂和其用途
ES2974657T3 (es) Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
EP3853228A1 (en) Inhibitors of human immunodeficiency virus replication
JP7545414B2 (ja) ヒト免疫不全ウイルス複製阻害剤
EP4041729B1 (en) Inhibitors of human immunodeficiency virus replication
JP2022551254A (ja) ヒト免疫不全ウイルスの複製阻害剤
WO2021176366A1 (en) Inhibitors of human immunodeficiency virus replication
JP2023521460A (ja) ヒト免疫不全ウイルス複製の阻害剤
TWI879947B (zh) 取代的氮雜五元環類化合物及其在藥物中的應用
BR122024005456A2 (pt) Compostos inibidores de replicação do vírus da imunodeficiência humana, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos no tratamento de infecção por hiv
HK40124048A (zh) Rip1抑制性化合物以及制备和使用其的方法
HK40124049A (zh) Rip1抑制性化合物以及制备和使用其的方法